
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
May 18, 2016.
Forbes
reports that Valeant Pharmaceuticals is planning to pay CFO Robert L. Rosiello and executives Dr. Ari Kellen and Anne C. Whitaker $1 million retention bonuses, as well as “special equity awards” of $2.8 million, $3.8 million and $1.25 million, respectively, in the form of restricted stock units that vest over 18-months. Antoine Gara writes that these heavy retention bonuses "further indicate pay will be a big part of working for a kinder and gentler Valeant. Or," he adds, "perhaps, Valeant has become such a toxic workplace only heavy incentives can generate loyalty inside the company".
